A Phase 2/3 interventional study of Mitapivat and Mitapivat-matching placebo in Sickle Cell Disease, sponsored by Agios Pharmaceuticals, Inc.. Active, not recruiting at 91 sites in 16 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Agios Pharmaceuticals, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.
Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 33rd largest by enrollment of the 559 interventional ones that give a count, is one of 41 that started in 2022, is one of 7 in phase 2/3, reaches primary completion later than 19 of the 182 other live ones, and was the 560th registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:
University of Maryland, Baltimore · Sites in United States
Ages 18–88
Mohsen Saidinejad · Sites in United States
Ages 5–20
St. Jude Children's Research Hospital · Sites in United States
Ages up to 22
Emory University · Sites in United States
Ages 8–18
University of Alabama at Birmingham · Sites in United States
Ages 18–50 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
733 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 158 · Phase 2 228 · Phase 3 57 · Phase 4 20
First in 1984; this study’s year is marked. 41 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 286 is above the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 31 across the 559 interventional studies, 100 across the 168 observational. Of the 506 that completed or were terminated, 207 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
168 of 733 have an industry lead sponsor. The 10 most frequent:
Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.
Agios Pharmaceuticals, Inc. has 6 studies filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
57 of the studies in Anemia, Sickle Cell with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07247188Phase 3SanofiStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease | 2027-01-07 |
| NCT04293185Phase 3bluebird bioA Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease | 2027-05 |
| NCT06989567Phase 3Asklepion Pharmaceuticals, LLCA Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis | 2027-06 |
| NCT05329649Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) | 2027-06-06 |
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
Add all 57 to your calendar (.ics) → With an account.
Among the 733 studies in Anemia, Sickle Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial is a Phase 2/3 study that will determine the recommended dose of mitapivat and evaluate the efficacy and safety of mitapivat in sickle cell disease by testing how well mitapivat works compared to placebo to increase the amount of hemoglobin in the blood and to reduce or prevent the occurrence of sickle cell pain crises. In addition, the long-term effect of mitapivat on efficacy and safety will be explored in an open-label extension portion.
Mitapivat is a small molecule, oral activator of pyruvate kinase R (PKR). PKR is involved with maintaining health, energy, and longevity of red blood cells (RBCs). The study aims to evaluate the efficacy and safety of treatment with mitapivat in participants with sickle cell disease. The study is a Phase 2/3 study in which the recommended dose of mitapivat will be selected and further evaluated. The Phase 2 portion includes a 12-week randomized, placebo-controlled period in which participants will be randomized in a 1:1:1 ratio to receive 2 dose levels of mitapivat or placebo. The Phase 3 portion includes a 52-week randomized, placebo-controlled period in which participants will be randomized in a 2:1 ratio to receive the recommended mitapivat dose level or placebo. Participants who complete either the Phase 2 or Phase 3 portion will have the option to move into a 216-week open label extension period to receive mitapivat.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-blind Period: Mitapivat 50 milligrams (mg) twice daily (BID) for 12 weeks.
Drug: Mitapivat
Double-blind Period: Mitapivat 100 mg BID for 12 weeks.
Drug: Mitapivat
Double-blind Period: Mitapivat-matching placebo for 12 weeks.
Other: Mitapivat-matching placebo
Participants who received mitapivat 50mg BID in the double-blind period may choose to receive mitapivat 50mg BID for 216 weeks after. Participants who received mitapivat 100mg BID in the double-blind period may choose to receive mitapivat 100 mg BID for 216 weeks after. Participants who received mitapivat-matching placebo in the double-blind period, may be randomized to receive either mitapivat 50 mg or 100 mg BID for 216 weeks after.
Drug: Mitapivat
Double-blind Period: Mitapivat 100 mg BID for 52 weeks.
Drug: Mitapivat
Double-blind Period: Mitapivat-matching placebo for 52 weeks.
Other: Mitapivat-matching placebo
Participants may choose to receive mitapivat 100 mg BID for 216 weeks after the Double-blind Period. Participants who received mitapivat-matching placebo in the double-blind period, may choose to receive mitapivat 100 mg BID for 216 weeks after the Double-blind Period.
Drug: Mitapivat
Mitapivat tablets
Also known as: AG-348, Mitapivat Sulfate
Placebo to match 50 mg or 100 mg tablets
Placebo to match 100 mg tablets
Phase 2: Percentage of Participants With Hemoglobin (Hb) Response
Time frame: Week 12
Phase 2: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious AEs (SAEs)
Time frame: Up to Week 12
Phase 3: Percentage of Participants With Hb Response
Time frame: Week 52
Phase 3: Annualized Rate of Sickle Cell Pain Crises (SCPCs)
Time frame: Up to Week 52
Phase 2: Change From Baseline in Hb Concentration
Time frame: Baseline, Week 10 up to Week 12
Phase 2: Change From Baseline in Indirect Bilirubin
Time frame: Baseline, Week 10 up to Week 12
Phase 2: Change From Baseline in Lactate Dehydrogenase (LDH)
Time frame: Baseline, Week 10 up to Week 12
Phase 2: Change From Baseline in Absolute Reticulocytes Count
Time frame: Baseline, Week 10 up to Week 12
Phase 2: Change From Baseline in Percent Reticulocytes
Time frame: Baseline, Week 10 up to Week 12
Phase 2: Change From Baseline in Erythropoietin
Time frame: Baseline, Week 10 up to Week 12
Phase 2: Change From Baseline in Patient-Reported Outcomes Measurement Information System® (PROMIS®) Fatigue 13a Short Form (SF) Score
Time frame: Baseline, Week 10 up to Week 12
Phase 2: Annualized Rate of SCPCs
Time frame: Up to Week 12
Phase 2: Pharmacokinetic/Pharmacodynamic Relationship: Evaluate the Exposure of Mitapivat to the Change in Adenosine Triphosphate (ATP) and 2,3-Diphosphoglycerate (2,3-DPG)
Time frame: Day 1 up to Week 8
Phase 2: Mitapivat Concentration Over Time
Time frame: Day 1 up to Week 8
Phase 2: Mitapivat Area Under the Concentration
Time frame: Day 1 up to Week 8
Phase 2: Mitapivat Maximum (Peak) Concentration
Time frame: Day 1 up to Week 8
Phase 3: Change From Baseline in Hb Concentration
Time frame: Baseline, Week 24 up to Week 52
Phase 3: Change From Baseline in Indirect Bilirubin
Time frame: Baseline, Week 24 up to Week 52
Phase 3: Change From Baseline in Percent Reticulocytes
Time frame: Baseline, Week 24 up to Week 52
Phase 3: Change From Baseline in PROMIS® Fatigue 13a SF Scores
Time frame: Baseline, Week 24 up to Week 52
Phase 3: Annualized Frequency of Hospitalizations for SCPC
Time frame: Up to Week 52
Phase 3: Change From Baseline in LDH Concentration
Time frame: Baseline, Week 24 up to Week 52
Phase 3: Change From Baseline in Absolute Reticulocytes
Time frame: Baseline, Week 24 up to Week 52
Phase 3: Change From Baseline in Erythropoietin
Time frame: Baseline, Week 24 up to Week 52
Phase 3: Percentage of Participants With Improvement in the Patient Global Impression of Severity (PGIS) -Fatigue
Time frame: Baseline, Weeks 24, 28, 40, and 52
Phase 3: Percentage of Participants With Improvement in the Patient Global Impression of Change (PGIC) -Fatigue
Time frame: Baseline, Weeks 24, 28, 40, and 52
Phase 3: Time to First SCPC
Time frame: Up to Week 52
Phase 3: Time to Second SCPC
Time frame: Up to Week 52
Phase 3: Annualized Rate of Hospitalization Days for SCPC
Time frame: Up to Week 52
Phase 3: Annualized Rate of Emergency Room Visits for SCPC
Time frame: Up to Week 52
Phase 3: Change From Baseline in 6-Minute Walk Test (6MWT)
Time frame: Baseline, Week 52
Phase 3: Change From Baseline in PROMIS Pain Intensity
Time frame: Baseline, Week 24 and 52
Phase 3: Change From Baseline in Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) Pain Impact
Time frame: Baseline, Week 24 and 52
Phase 3: PGIC of Pain
Time frame: Baseline, Week 52
Phase 3: Change From Baseline in PGIS of Pain
Time frame: Baseline, Week 52
Phase 3: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious AEs (SAEs)
Time frame: Up to 56 weeks
Phase 3: Pharmacokinetic/Pharmacodynamic Relationship: Evaluate the Exposure of Mitapivat to the Change in ATP and 2,3-DPG Levels
Time frame: Day 1 up to Week 40
Phase 3: Mitapivat Concentration Over Time
Time frame: Day 1 up to Week 40
Phase 3: Mitapivat Area Under the Concentration Curve
Time frame: Day 1 up to Week 40
Phase 3: Mitapivat Maximum (Peak) Concentration
Time frame: Day 1 up to Week 40
Plan to share: No
Ran from Feb 2022 to primary completion in Oct 2025, 44 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mitapivat